Nimotuzumab in the Treatment of Inoperable Esophageal Tumors of Epithelial Origin

BACKGROUND: Nimotuzumab is a humanized monoclonal antibody that targets the epidermal growth factor receptor. It was approved in Cuba for the indication of inoperable malignant tumors of the esophagus of epithelial origin. The purpose of this study was to evaluate the safety, overall and progression...

Descripción completa

Detalles Bibliográficos
Autores principales: González Fernández, Sandra, Amador García, Yohan, Boris Porras, Lucien Gregoria, Mojena Martínez, Liuba, Soler Porro, Luis Laureano, Pish Martí, Gustavo, Fonseca Chon, Liem, Estrada Guerra, Yelec, Álvarez Blanco, Jorge Manuel, Garabito Perdomo, Acralys, Santel Odio, Félix Bárbaro, Varona Vázquez, Luis Alfonso, Ricardo Serrano, Yoel Mario, Chao González, Lisette, Avila Albuerne, Yisel, Sánchez Valdés, Lizet, Viada González, Carmen Elena, Ramos Suzarte, Mayra, Saumell Nápoles, Yaimarelis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9458364/
https://www.ncbi.nlm.nih.gov/pubmed/36090901
http://dx.doi.org/10.1155/2022/4128946

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9458364/
https://www.ncbi.nlm.nih.gov/pubmed/36090901
http://dx.doi.org/10.1155/2022/4128946

Ejemplares similares